Hematologic effects of recombinant factor VIIa combined with hemoglobin-based oxygen carrier-201 for prehospital resuscitation of swine with severe uncontrolled hemorrhage due to liver injury

Blood Coagulation and Fibrinolysis

Volumn 19, Issue 7, 2008, Pages 669-677

  Arnaud, Françoise ^a   Hammett, Michael ^a   Philbin, Nora ^a   Scultetus, Anke ^a,b   McCarron, Richard ^a,b   Freilich, Daniel ^a,b  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Coagulation; Hemorrhagic shock; Hemostasis; Resuscitation; Trauma; Uncontrolled bleeding

Indexed keywords

ELECTROLYTE; HEMOGLOBIN BASED OXYGEN CARRIER 201; OXYHEMOGLOBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SODIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLOOD CELL COUNT; BLOOD CLOTTING DISORDER; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE ESCALATION; FLUID RESUSCITATION; HEMATOCRIT; HEMOSTASIS; HYPOTENSION; LIVER INJURY; NONHUMAN; PRIORITY JOURNAL; PROTHROMBIN TIME; REACTION TIME; SHOCK; STATISTICAL ANALYSIS; SURVIVAL; SWINE; TACHYCARDIA; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

ANIMALS; BLEEDING TIME; BLOOD COAGULATION; BLOOD SUBSTITUTES; BLOOD TRANSFUSION; DISEASE MODELS, ANIMAL; FACTOR VIIA; FLUID THERAPY; HEMATOLOGIC TESTS; HEMOGLOBINS; INFUSIONS, INTRAVENOUS; LIVER; PLATELET COUNT; PROTHROMBIN TIME; RECOMBINANT PROTEINS; RESUSCITATION; SHOCK, HEMORRHAGIC; SWINE; SWINE, MINIATURE; THROMBELASTOGRAPHY;

EID: 55049108992     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283089198     Document Type: Article

References (37)

1. Holcomb JB, Jenkins D, Rhee P, Johannigman J, Mahoney P, Mehta S, et al. Damage control resuscitation: directly addressing the early coagulopathy of trauma. J Trauma 2007; 62:307-310.
2. Tieu BH, Holcomb JB, Schreiber MA. Coagulopathy: its pathophysiology and treatment in the injured patient. World J Surg 2007; 31:1056-1065.
3. Cosgriff N, Moore EE, Sauaia A, Kenny-Moynihan M, Burch JM, Galloway B. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidoses revisited. J Trauma 1997; 42:857-861.
4. Brohi K, Singh J, Heron M, Coats T. Acute traumatic coagulopathy. J Trauma 2003; 54:1127-1130.
5. Mannucci M, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007; 356:2300-2310.
6. Hedner U, Erhardtsen E. Potential role of recombinant factor VIIa as a hemostatic agent. Clin Adv Hematol Oncol 2003; 1:112-119.
7. Poon MC, d'Orion R, von Depka M, Khair K, Negrier C, Karafoulidou A. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombastenia. Results of an international survey. J Thromb Haemost 2004; 2:1096-1103.
8. Silva MA, Muralidharan V, Mirza DF. The management of coagulopathy and blood loss in liver surgery. Semin Hematol 2004; 41 (Suppl):132-139.
9. Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharisei E, Papaioannou M, et al. Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. Am J Hematol 2002; 69:219-222.
10. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33:883-890.
11. O'Neill PA, Bluth M, Gloster ES, Wali D, Priovolos S, DiMaio TM, et al. Successful use of recombinant activated factor VII for trauma-associated hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002; 52:400-405.
12. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding: a European perspective. Crit Care 2006; 10:R120.
13. Dutton RP, McCunn M, Hyder M, D'Angelo M, O'Connor J, Hess JR, Scalea TM. Factor VIIa for correction of traumatic coagulopathy. J Trauma 2004; 57:709-718.
14. Boffard KD, Riou B, Warren B, et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59:8-15.
15. Rizoli SB, Chughtai T. The emerging role of recombinant activated factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage. Expert Opin Biol Ther 2006; 6:73-81.
16. Harrison TD, Laskosky J, Jazaeri O, Pasquale MD, Cipolle M. 'Low-dose' recombinant activated factor VII results in less blood and blood product use in traumatic hemorrhage. J Trauma 2005; 59:150-154.
17. Pusateri AE, Ryan KL, Delgado AV, Martinez RS, Uscilowicz JM, Cortez DS, Martinowitz U. Effects of increasing doses of activated recombinant factor VII on haemostatic parameters in swine. Thromb Haemost 2005; 93:275-283.
18. Schreiber MA, Holcomb JB, Rojkjaer R. Preclinical trauma studies of recombinant factor VIIa. Crit Care 2005; 9 (Suppl 5):S25-S28.
19. Martinowitz U, Holcomb JB, Pusateri AE, Stein M, Onaca N, Freidman M, et al. Intravenous rFVIIa administered for hemorrhage control in hypothermic coagulopathic swine with grade V liver injuries. J Trauma 2001; 50:721-729.
20. Allen GA, Hoffman M, Roberts HR, Monroe DM 3rd. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Can J Anaesth 2002; 9:S7-S14.
21. Gabriel DA, Li X, Monroe DM 3rd, Roberts HR. Recombinant human factor VIIa (rFVIIa) can activate factor FIX on activated platelets. J Thromb Haemost 2004; 2:1816-1822.
22. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95:594-599.
23. Thomas GO, Dutton RP, Hemlock B, Stein DM, Hyder M, Shere-Wolfe R, et al. Thromboembolic complications associated with factor VIIa administration. J Trauma 2007; 62:564-569.
24. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295:293-298.
25. Perkins JG, Schreiber MA, Wade CE, Holcomb JB. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion. J Trauma 2007; 62:1095-1099.
26. MacLeod JB, Lynn M, McKenney MG, Cohn S, Martha M. Early coagulopathy predicts mortality in trauma. J Trauma 2003; 55:39-44.
27. Gurney J, Philbin N, Rice J, Arnaud F, Dong F, Wulster-Radcliffe M, et al. A hemoglobin based oxygen carrier, bovine polymerized hemoglobin (HBOC-201) versus hetastarch (HEX) in an uncontrolled liver injury hemorrhagic shock swine model with delayed evacuation. J Trauma 2004; 57:726-738.
28. Arnaud F, Handrigan M, Hammett M, Philbin N, Rice J, Dong F, et al. Coagulation patterns following haemoglobin-based oxygen carrier resuscitation in severe uncontrolled haemorrhagic shock in swine. Transfus Med 2006; 16:290-302.
29. Manning JE, Katz LM, Brownstein MR, Pearce LB, Gawryl MS, Baker CC, and the Carolina Resuscitation Research Group. Bovine hemoglobin-based oxygen carrier (HBOC-201) for resuscitation of uncontrolled, exsanguinating liver injury in swine. Shock 2000; 13:152-159.
30. Schulman S, rFVIIa-CI Group. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness. Semin Thromb Hemost 2000; 26:421-424.
31. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000; 26:385-391.
32. Sapsford W, Watts S, Cooper G, Kirkman E. Recombinant activated factor VII increases survival time in a model of incompressible arterial hemorrhage in the anesthetized pig. J Trauma 2007; 62:868-879.
33. Meng ZH, Wolberg AS, Monroe DM 3rd, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients. J Trauma 2003; 55:886-891.
34. Holcomb JB. Use of recombinant activated factor VII to treat the acquired coagulopathy of trauma J Trauma 2005; 58:1298-1303.
35. Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl 1):S61-S65.
36. Kenet G, Nowak-Gottl U. Bleeding and thrombosis issues in pediatric patients: current approach to diagnosis and treatment. Acta Haematol 2006; 115:137-140.
37. Roberts HR, Monroe DM 3rd, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41 (Suppl 4):101-108.